UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 266

Sortiert nach

Aberrant Intermolecular Disulfide Bonding in a Mutant HLA-DM Molecule: Implications for Assembly, Maturation, and Function

The Journal of immunology (1950), 1998-01, Vol.160 (2), p.734-743

1998

Volltextzugriff (PDF)

Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1100-1100

2022

Volltextzugriff (PDF)

Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1102-1102

2022

Volltextzugriff (PDF)

Abstract 1103: MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1103-1103

2022

Volltextzugriff (PDF)

Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1174-1174

2022

Volltextzugriff (PDF)

Abstract 1842: Novel KIF5B-RET + NSCLC cell lines demonstrate differential responses to RET inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1842-1842

2018

Volltextzugriff (PDF)

Abstract 1865: Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1865-1865

2020

Volltextzugriff (PDF)

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2202-2202

2019

Volltextzugriff (PDF)

Abstract 2379: Rap1 regulates angiogenesis in prostate tumors

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2379-2379

2010

Volltextzugriff (PDF)

Abstract 3003: MET mediates entrectinib resistance in ROS1 gene fusion positiveNSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3003-3003

2020

Volltextzugriff (PDF)

Abstract 3467: A novel interplay between Rap1, Epac and PKA regulates induction of angiogenesis

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3467-3467

2011

Volltextzugriff (PDF)

Abstract 3878: Bach1 promotes liver metastasis of colorectal cancer cells by regulating c-Myc and SOX4

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3878-3878

2013

Volltextzugriff (PDF)

Abstract 3936: ALK fusion oncogene driven SERPINB4 expression enhances tumor survival in NSCLC

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3936-3936

2023

Volltextzugriff (PDF)

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3984-3984

2022

Volltextzugriff (PDF)

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4025-4025

2019

Volltextzugriff (PDF)

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.442-442

2019

Volltextzugriff (PDF)

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4529-4529

2015

Volltextzugriff (PDF)

Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4766-4766

2018

Volltextzugriff (PDF)

Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5233-5233

2022

Volltextzugriff (PDF)

Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5255-5255

2014

Volltextzugriff (PDF)

Abstract 5262: Identifying the role of AXL in fusion kinase inhibitor resistant non-small cell lung cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5262-5262

2020

Volltextzugriff (PDF)

Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5594-5594

2012

Volltextzugriff (PDF)

Abstract 5785: EML4-ALK variant E6a/b;A20 positive NSCLC cell lines are associated with growth upon blocking MEK-ERK pathway

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5785-5785

2018

Volltextzugriff (PDF)

Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.812-812

2010

Volltextzugriff (PDF)

Abstract 894: Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.894-894

2012

Volltextzugriff (PDF)

1 – 25 von 266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(245)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

Englisch
(266)
Japanisch
(52)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(125)
Life Sciences & Biomedicine
(122)
Humans
(112)
Oncology
(99)
Lung Neoplasms - Drug Therapy
(56)
Lung Neoplasms - Genetics
(51)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(49)
Male
(47)
Female
(46)
Carcinoma, Non-Small-Cell Lung - Genetics
(45)
Middle Aged
(41)
Lung Neoplasms - Pathology
(39)
Lung Cancer
(38)
Mutation
(36)
Carcinoma, Non-Small-Cell Lung - Pathology
(33)
Aged
(30)
Respiratory System
(29)
Adult
(28)
Protein Kinase Inhibitors - Therapeutic Use
(28)
Tumors
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Aberrant Intermolecular Disulfide Bonding in a Mutant HLA-DM Molecule: Implications for Assembly, Maturation, and Function

Abstract 1100: miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling

Abstract 1102: Fyn and Src cooperate with ERBB family to drive resistance to crizotinib in ROS1+ and ALK+ NSCLC

Abstract 1103: MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors

Abstract 1842: Novel KIF5B-RET + NSCLC cell lines demonstrate differential responses to RET inhibitors

Abstract 1865: Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers

Abstract 2379: Rap1 regulates angiogenesis in prostate tumors

Abstract 3003: MET mediates entrectinib resistance in ROS1 gene fusion positiveNSCLC

Abstract 3467: A novel interplay between Rap1, Epac and PKA regulates induction of angiogenesis

Abstract 3878: Bach1 promotes liver metastasis of colorectal cancer cells by regulating c-Myc and SOX4

Abstract 3936: ALK fusion oncogene driven SERPINB4 expression enhances tumor survival in NSCLC

Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

Abstract 4766: The Global ROS1 Initiative: A patient-researcher partnership generating open-source, oncogene-driven cancer models and data

Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC

Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer

Abstract 5262: Identifying the role of AXL in fusion kinase inhibitor resistant non-small cell lung cancer

Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance

Abstract 5785: EML4-ALK variant E6a/b;A20 positive NSCLC cell lines are associated with growth upon blocking MEK-ERK pathway

Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events

Abstract 894: Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer

Suchergebnisse filtern